Log in

LON:PRTC - PureTech Health Share Price, Forecast & News

GBX 254
+2.00 (+0.79 %)
(As of 12/6/2019 04:00 PM ET)
Add
Today's Range
249
Now: GBX 254
265
50-Day Range
219
MA: GBX 256.62
290
52-Week Range
155.50
Now: GBX 254
307
Volume89,964 shs
Average Volume71,917 shs
Market Capitalization£724.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-617-4822333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£20.16 million
Cash FlowGBX 66.06 per share
Book ValueGBX 124 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£724.57 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PRTC News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.


PureTech Health (LON:PRTC) Frequently Asked Questions

What is PureTech Health's stock symbol?

PureTech Health trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

What price target have analysts set for PRTC?

4 equities research analysts have issued 12-month price targets for PureTech Health's stock. Their forecasts range from GBX 300 to GBX 460. On average, they expect PureTech Health's share price to reach GBX 390 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price. View Analyst Price Targets for PureTech Health.

What is the consensus analysts' recommendation for PureTech Health?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PureTech Health in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PureTech Health.

Has PureTech Health been receiving favorable news coverage?

Media stories about PRTC stock have trended extremely positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PureTech Health earned a media sentiment score of 4.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for PureTech Health.

What other stocks do shareholders of PureTech Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PureTech Health investors own include Nemaska Lithium (NMX), Yamana Gold (YRI), Chaarat Gold (CGH), Polo Resources (POL), Arotech (ARTX), Baozun (BZUN), Kratos Defense & Security Solutions (KTOS), Rewalk Robotics (RWLK), Boeing (BA) and CarMax (KMX).

Who are PureTech Health's key executives?

PureTech Health's management team includes the folowing people:
  • Ms. Daphne Zohar, Founder, CEO & Exec. Director (Age 47)
  • Dr. Bennett M. Shapiro, Co-Founder & Non-Exec. Director (Age 78)
  • Dr. Robert S. Langer Jr., Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 69)
  • Mr. Stephen M. Muniz J.D., COO, Exec. VP of Legal & Operations, Sec. and Exec. Director (Age 48)
  • Dr. Bharatt M. Chowrira, Pres and Chief of Bus. & Strategy (Age 53)

How do I buy shares of PureTech Health?

Shares of PRTC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is PureTech Health's stock price today?

One share of PRTC stock can currently be purchased for approximately GBX 254.

How big of a company is PureTech Health?

PureTech Health has a market capitalization of £724.57 million and generates £20.16 million in revenue each year. View Additional Information About PureTech Health.

What is PureTech Health's official website?

The official website for PureTech Health is http://puretechhealth.com/.

How can I contact PureTech Health?

PureTech Health's mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The company can be reached via phone at +1-617-4822333.


MarketBeat Community Rating for PureTech Health (LON PRTC)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  471 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  615
MarketBeat's community ratings are surveys of what our community members think about PureTech Health and other stocks. Vote "Outperform" if you believe PRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: Stock Portfolio Tracker

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel